Sanofi Pasteur

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

Retrieved on: 
Wednesday, December 20, 2023

These included the immediate transition from the Company’s two-tier governance model to a one-tier model led by a Board of Directors.

Key Points: 
  • These included the immediate transition from the Company’s two-tier governance model to a one-tier model led by a Board of Directors.
  • During a constitutional post-EGM meeting, Valneva’s former Supervisory Board member Anne-Marie Graffin was elected as Chair of the Company’s new Board of Directors.
  • Ms. Graffin is Vice Chair of Nanobiotix’s Supervisory Board, member of the Sartorius Stedim Biotech Board of Directors and member of Vetoquinol S.A Board of Directors.
  • Anne-Marie Graffin, Chair of Valneva´s Board of Directors, commented, “I would like to thank all departing Supervisory Board members for their contributions and the newly elected Board of Directors members for their trust.

The 2023 Global Investment Promotion Conference Held in Shenzhen, China

Retrieved on: 
Friday, December 8, 2023

Shenzhen, an open city, is extending invitations to global investors. Under the theme of "Create New Paradigms, Embrace Shared Opportunities -- Invest in Shenzhen, Build a Winning Future", the Conference took place in the format of "1+1+12+N" events, according to the Commerce Bureau of Shenzhen Municipality. Specifically, it consists of one main event, namely the Investment Promotion Conference and the Shenzhen City Summary Meeting on Investment Promotion; one Investment Outcome Exhibition Area; 12 district-level investment promotion conferences; and several overseas parallel sessions and industrial investment promotion activities. Ten overseas parallel sessions were staged in Madrid, Zurich, Hawaii, Vancouver, San Diego, Brisbane, Chicago, Tokyo, Sydney, and Milan. 12 industry investment promotion activities were held on various topics, including energy storage, digital energy, finance, consumption, talent attraction, and high-tech industries.

Key Points: 
  • SHENZHEN, China, Dec. 8, 2023 /PRNewswire/ -- On December 8, the 2023 Shenzhen Global Investment Promotion Conference was held in Shenzhen, China.
  • Specifically, it consists of one main event, namely the Investment Promotion Conference and the Shenzhen City Summary Meeting on Investment Promotion; one Investment Outcome Exhibition Area; 12 district-level investment promotion conferences; and several overseas parallel sessions and industrial investment promotion activities.
  • 12 industry investment promotion activities were held on various topics, including energy storage, digital energy, finance, consumption, talent attraction, and high-tech industries.
  • The Conference showcased investment opportunities and policies for investing in Shenzhen as well as presented Shenzhen's first-class business environment to the world.

The 2023 Global Investment Promotion Conference Held in Shenzhen, China

Retrieved on: 
Friday, December 8, 2023

Shenzhen, an open city, is extending invitations to global investors. Under the theme of "Create New Paradigms, Embrace Shared Opportunities -- Invest in Shenzhen, Build a Winning Future", the Conference took place in the format of "1+1+12+N" events, according to the Commerce Bureau of Shenzhen Municipality. Specifically, it consists of one main event, namely the Investment Promotion Conference and the Shenzhen City Summary Meeting on Investment Promotion; one Investment Outcome Exhibition Area; 12 district-level investment promotion conferences; and several overseas parallel sessions and industrial investment promotion activities. Ten overseas parallel sessions were staged in Madrid, Zurich, Hawaii, Vancouver, San Diego, Brisbane, Chicago, Tokyo, Sydney, and Milan. 12 industry investment promotion activities were held on various topics, including energy storage, digital energy, finance, consumption, talent attraction, and high-tech industries.

Key Points: 
  • SHENZHEN, China, Dec. 8, 2023 /PRNewswire/ -- On December 8, the 2023 Shenzhen Global Investment Promotion Conference was held in Shenzhen, China.
  • Specifically, it consists of one main event, namely the Investment Promotion Conference and the Shenzhen City Summary Meeting on Investment Promotion; one Investment Outcome Exhibition Area; 12 district-level investment promotion conferences; and several overseas parallel sessions and industrial investment promotion activities.
  • 12 industry investment promotion activities were held on various topics, including energy storage, digital energy, finance, consumption, talent attraction, and high-tech industries.
  • The Conference showcased investment opportunities and policies for investing in Shenzhen as well as presented Shenzhen's first-class business environment to the world.

AuraVax Therapeutics Appoints Two Healthcare Veterans to its Board of Directors

Retrieved on: 
Tuesday, November 28, 2023

HOUSTON, Nov. 28, 2023 /PRNewswire/ -- AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced that Thomas Finn and John Shiver have joined the company's board of directors. They will serve with Laurence Cooper who is the chair of AuraVax's board.

Key Points: 
  • They join AuraVax at an exciting time as our lead product, NanoSTING-001, advances to clinical testing.
  • Finn serves as a Board member of Cincinnati Children's Medical Center and is Chair of their Research Committee.
  • He also serves as a Board member for Eikonoklastes Therapeutics, a Biotech company developing gene therapy for amyotrophic lateral sclerosis.
  • Shiver also serves as a board member of Icosavax Inc and IAVI Boards of Directors.

Sanofi Bridging the Gap between the Homeless and Society via Futsal

Retrieved on: 
Tuesday, October 17, 2023

Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream’ together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless.

Key Points: 
  • Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream’ together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless.
  • Sanofi sponsored the foundation of the ‘Dream’ as part of its decade-long homeless program Helping Hands, wishing to go beyond protecting rights to health, and highlight the cultural and sports rights of the homeless.
  • Helping Hands is Korea’s largest homeless free flu vaccination program operated by targeting the homeless and housing-vulnerable groups in medical service blind spots.
  • Sanofi has operated this program since 2011, contributing to preventing social disconnection of the homeless in addition to promoting the right to health of the homeless.

Uvax Bio Appoints Pedro Garbes, MD., as Vice President, Global Medical Lead

Retrieved on: 
Wednesday, September 13, 2023

Uvax Bio LLC, a vaccine biotechnology company that utilizes its proprietary 1c-SApNP® vaccine design and manufacturing platform to produce protein-based VLP vaccines to fight viruses that threaten global health, announced today that Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead.

Key Points: 
  • Uvax Bio LLC, a vaccine biotechnology company that utilizes its proprietary 1c-SApNP® vaccine design and manufacturing platform to produce protein-based VLP vaccines to fight viruses that threaten global health, announced today that Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead.
  • Dr. Garbes joins Uvax Bio at a key inflection point as the company’s recombinant protein nanoparticle vaccines are advancing in development.
  • "We are pleased to have Pedro join our leadership team as we prepare to take our lead vaccines to the next stage of development.
  • Pedro Garbes brings to Uvax Bio over two decades of life sciences experience in clinical vaccine development, medical affairs, and medical/commercial strategy.

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

Retrieved on: 
Tuesday, June 27, 2023

WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.

Key Points: 
  • WARRINGTON, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.
  • Craig Fraser, Windtree's President and Chief Executive Officer said, “We are pleased to welcome Mark as a new independent director to Windtree's Board of Directors.
  • Mark will be highly complementary to our existing Board of Directors which includes Dan Geffkin, Leslie Williams, Dr.
  • The Company has a number of strategic opportunities and clinical milestones ahead and I look forward to supporting Windtree to help drive value for patients and shareholders."

Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board

Retrieved on: 
Tuesday, May 30, 2023

(“Clarametyx”), a clinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of Dr. Jeffrey Almond to the company’s scientific advisory board (SAB).

Key Points: 
  • (“Clarametyx”), a clinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of Dr. Jeffrey Almond to the company’s scientific advisory board (SAB).
  • He was previously the global head of research at Sanofi Pasteur, and a professor at the University of Reading.
  • He has published extensively in the field of virology and vaccination and has served in numerous advisory roles addressing significant global viral and bacterial microbiological threats.
  • Prior to joining UroGen, Dr. Seltzer served as Chief Medical Officer of Nabriva Therapeutics where she was responsible for the company’s clinical development of Xenleta (lefamulin) for community-acquired pneumonia.

Global mRNA Synthesis Raw Materials Market Report 2023: Increasing Funding For mRNA Research Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 12, 2023

The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030.

Key Points: 
  • The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030.
  • The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research.
  • In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.
  • The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases.

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Retrieved on: 
Monday, April 3, 2023

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.
  • Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones.
  • Nabors brings an exceptional wealth of experience and established results to Appili, and he will play a critical role in advancing our programs and our business,” said Dr. Don Cilla, President and Chief Executive Officer of Appili Therapeutics.
  • He has played a central role in product development from pre-clinical stages through to Phase 3, for development of vaccines and therapeutics for pediatric, adult, and biodefense markets.